<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472885</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-101</org_study_id>
    <secondary_id>2016-003526-16</secondary_id>
    <secondary_id>U1111-1209-4655</secondary_id>
    <nct_id>NCT03472885</nct_id>
  </id_info>
  <brief_title>Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab</brief_title>
  <acronym>PNH</acronym>
  <official_title>A Phase 2 Open-label Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Achillion, a wholly owned subsidiary of Alexion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effectiveness of ACH-0144471 (also known as danicopan and ALXN2040) in&#xD;
      improving anemia when given with eculizumab for 24 weeks in participants with PNH. Danicopan&#xD;
      dose may be increased within each participant, to a maximum of 200 milligrams (mg) three&#xD;
      times daily (TID) based on safety and efficacy at protocol-specified time points.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the effectiveness of danicopan in improving anemia,&#xD;
      as measured by increased blood hemoglobin, when given with eculizumab (a drug commonly used&#xD;
      for treatment of PNH) for 24 weeks in participants with PNH.&#xD;
&#xD;
      The 24-week treatment period was followed by a long-term extension phase (ongoing). In the&#xD;
      extension phase, participants receive the same danicopan dose plus eculizumab as they were&#xD;
      receiving at the end of 24-week treatment phase.&#xD;
&#xD;
      Results are reported for the 24-week treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 8, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Actual">September 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Four groups will be studied and enrolled sequentially.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline In Hemoglobin At Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number Of Units Of Red Blood Cells (RBCs) Transfused During 24 Weeks Of Treatment</measure>
    <time_frame>From 24 weeks prior to first dose through 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Participants Without RBC Transfusions</measure>
    <time_frame>From 24 weeks prior to first dose through 24 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Lactate Dehydrogenase At Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Participants With Serious Adverse Events (SAEs), Grade 3 And Grade 4 Adverse Events (AEs), And Events Leading To Discontinuation Of Study Drug</measure>
    <time_frame>Day 1 (after dosing) through 24 weeks</time_frame>
    <description>An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. The intensity of an AE was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Adverse Event Severity Grading Table. Laboratory abnormalities were determined from laboratory measurements analyzed at the central or local laboratories, and were graded using CTCAE. A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria (PNH)</condition>
  <arm_group>
    <arm_group_label>Group 1: 100 mg Danicopan TID + Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose of 100 mg danicopan TID in combination with eculizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Initial dose 100 or 150 mg Danicopan TID + Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose of 100 or 150 mg danicopan TID in combination with eculizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Initial dose of 100, 150, or 200 mg Danicopan TID + Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose of 100, 150, or 200 mg danicopan TID in combination with eculizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Optimal Dose of Danicopan TID + Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimal dose (starting dose of either 100, 150, or 200 mg, as determined from Groups 1-3) of danicopan TID in combination with eculizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Danicopan</intervention_name>
    <description>Participants received a daily oral dose of danicopan TID during the treatment period.</description>
    <arm_group_label>Group 1: 100 mg Danicopan TID + Eculizumab</arm_group_label>
    <arm_group_label>Group 2: Initial dose 100 or 150 mg Danicopan TID + Eculizumab</arm_group_label>
    <arm_group_label>Group 3: Initial dose of 100, 150, or 200 mg Danicopan TID + Eculizumab</arm_group_label>
    <arm_group_label>Group 4: Optimal Dose of Danicopan TID + Eculizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <description>Participants received intravenous eculizumab administered at the participant's usual dose and schedule.</description>
    <arm_group_label>Group 1: 100 mg Danicopan TID + Eculizumab</arm_group_label>
    <arm_group_label>Group 2: Initial dose 100 or 150 mg Danicopan TID + Eculizumab</arm_group_label>
    <arm_group_label>Group 3: Initial dose of 100, 150, or 200 mg Danicopan TID + Eculizumab</arm_group_label>
    <arm_group_label>Group 4: Optimal Dose of Danicopan TID + Eculizumab</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with PNH&#xD;
&#xD;
          -  Have received at least one red blood cell transfusion within last 12 weeks&#xD;
&#xD;
          -  Anemia with adequate reticulocytosis&#xD;
&#xD;
          -  Must be on a stable regimen of eculizumab&#xD;
&#xD;
          -  Platelet count â‰¥ 40,000/microliter without the need for platelet transfusions&#xD;
&#xD;
          -  Documentation of vaccination for Neisseria meningitidis, Haemophilus influenza, and&#xD;
             Streptococcus pneumoniae or willingness to receive vaccinations based on local&#xD;
             guidelines&#xD;
&#xD;
          -  Willingness to receive antibiotic prophylaxis&#xD;
&#xD;
          -  Female participants must use highly effective birth control to prevent pregnancy&#xD;
             during the clinical trial and for 30 days after their last dose of study drug&#xD;
&#xD;
          -  Male participants must use a highly effective birth control with a female partner to&#xD;
             prevent pregnancy during the clinical trial and for 90 days after the last dose of&#xD;
             study drug&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Current evidence of bone marrow failure or aplastic anemia requiring treatment&#xD;
&#xD;
          -  History of a major organ transplant or hematopoietic stem cell/marrow transplant&#xD;
&#xD;
          -  Received another investigational agent within 30 days or 5 half-lives of the&#xD;
             investigational agent prior to study entry, whichever is greater&#xD;
&#xD;
          -  Documented C5 complement protein mutations&#xD;
&#xD;
          -  Known or suspected complement deficiency&#xD;
&#xD;
          -  Contraindication to any of the required vaccinations&#xD;
&#xD;
          -  Active bacterial infection or clinically significant active viral infection, a body&#xD;
             temperature &gt;38Â°C, or other evidence of infection&#xD;
&#xD;
          -  History of meningococcal infection, or a first-degree relative or household contact&#xD;
             with a history of meningococcal infection&#xD;
&#xD;
          -  History of hypersensitivity reactions to commonly used antibacterial agents&#xD;
&#xD;
        Note: Additional inclusion/exclusion criteria may apply, per protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 15, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <results_first_submitted>June 3, 2021</results_first_submitted>
  <results_first_submitted_qc>June 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2021</results_first_posted>
  <disposition_first_submitted>October 27, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>October 27, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 5, 2020</disposition_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PNH</keyword>
  <keyword>Paroxysmal Nocturnal Hemoglobinuria</keyword>
  <keyword>ACH-0144471</keyword>
  <keyword>Danicopan</keyword>
  <keyword>Eculizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eculizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03472885/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 9, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03472885/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Danicopan + Eculizumab</title>
          <description>Participants were administered 100, 150, or 200 milligrams (mg) danicopan three times daily (TID) in combination with eculizumab. Danicopan dose may have been increased within each participant, to a maximum of 200 mg TID based on safety and efficacy.&#xD;
The study was based on a flexible dosing design. Data from all participants were pooled for analysis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population: Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Efficacy Population: Received Study Drug for at Least 4 Weeks</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population: Received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Danicopan + Eculizumab</title>
          <description>Participants were administered 100, 150, or 200 mg danicopan TID in combination with eculizumab. Danicopan dose may have been increased within each participant, to a maximum of 200 mg TID based on safety and efficacy.&#xD;
The study was based on a flexible dosing design. Data from all participants were pooled for analysis.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.60" spread="16.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline In Hemoglobin At Week 24</title>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Efficacy Population: All treated participants who receive at least 4 weeks of danicopan.</population>
        <group_list>
          <group group_id="O1">
            <title>Danicopan + Eculizumab</title>
            <description>Participants were administered 100, 150, or 200 mg danicopan TID in combination with eculizumab. Danicopan dose may have been increased within each participant, to a maximum of 200 mg TID based on safety and efficacy.&#xD;
The study was based on a flexible dosing design. Data from all participants were pooled for analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline In Hemoglobin At Week 24</title>
          <population>Efficacy Population: All treated participants who receive at least 4 weeks of danicopan.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.94" spread="1.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.33" spread="1.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="1.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Of Units Of Red Blood Cells (RBCs) Transfused During 24 Weeks Of Treatment</title>
        <time_frame>From 24 weeks prior to first dose through 24 weeks of treatment</time_frame>
        <population>Efficacy Population: All treated participants who receive at least 4 weeks of danicopan.</population>
        <group_list>
          <group group_id="O1">
            <title>Danicopan + Eculizumab</title>
            <description>Participants were administered 100, 150, or 200 mg danicopan TID in combination with eculizumab. Danicopan dose may have been increased within each participant, to a maximum of 200 mg TID based on safety and efficacy.&#xD;
The study was based on a flexible dosing design. Data from all participants were pooled for analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number Of Units Of Red Blood Cells (RBCs) Transfused During 24 Weeks Of Treatment</title>
          <population>Efficacy Population: All treated participants who receive at least 4 weeks of danicopan.</population>
          <units>RBC units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Within 24 Weeks Prior to First Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During 24-Week Treatment Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Of Participants Without RBC Transfusions</title>
        <time_frame>From 24 weeks prior to first dose through 24 weeks of treatment</time_frame>
        <population>Efficacy Population: All treated participants who receive at least 4 weeks of danicopan.</population>
        <group_list>
          <group group_id="O1">
            <title>Danicopan + Eculizumab</title>
            <description>Participants were administered 100, 150, or 200 mg danicopan TID in combination with eculizumab. Danicopan dose may have been increased within each participant, to a maximum of 200 mg TID based on safety and efficacy.&#xD;
The study was based on a flexible dosing design. Data from all participants were pooled for analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number Of Participants Without RBC Transfusions</title>
          <population>Efficacy Population: All treated participants who receive at least 4 weeks of danicopan.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Within 24 Weeks Prior to First Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>During 24-Week Treatment Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline In Lactate Dehydrogenase At Week 24</title>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Efficacy Population: All treated participants who receive at least 4 weeks of danicopan.</population>
        <group_list>
          <group group_id="O1">
            <title>Danicopan + Eculizumab</title>
            <description>Participants were administered 100, 150, or 200 mg danicopan TID in combination with eculizumab. Danicopan dose may have been increased within each participant, to a maximum of 200 mg TID based on safety and efficacy.&#xD;
The study was based on a flexible dosing design. Data from all participants were pooled for analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline In Lactate Dehydrogenase At Week 24</title>
          <population>Efficacy Population: All treated participants who receive at least 4 weeks of danicopan.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244.5" spread="74.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.5" spread="48.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="48.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Of Participants With Serious Adverse Events (SAEs), Grade 3 And Grade 4 Adverse Events (AEs), And Events Leading To Discontinuation Of Study Drug</title>
        <description>An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. The intensity of an AE was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Adverse Event Severity Grading Table. Laboratory abnormalities were determined from laboratory measurements analyzed at the central or local laboratories, and were graded using CTCAE. A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Day 1 (after dosing) through 24 weeks</time_frame>
        <population>Participants who received at least 1 dose of danicopan were included in the safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Danicopan + Eculizumab</title>
            <description>Participants were administered 100, 150, or 200 mg danicopan TID in combination with eculizumab. Danicopan dose may have been increased within each participant, to a maximum of 200 mg TID based on safety and efficacy.&#xD;
The study was based on a flexible dosing design. Data from all participants were pooled for analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Number Of Participants With Serious Adverse Events (SAEs), Grade 3 And Grade 4 Adverse Events (AEs), And Events Leading To Discontinuation Of Study Drug</title>
          <description>An AE was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An SAE was an AE that met at least 1 of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization for the AE, persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug), important medical event or reaction. The intensity of an AE was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Adverse Event Severity Grading Table. Laboratory abnormalities were determined from laboratory measurements analyzed at the central or local laboratories, and were graded using CTCAE. A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.</description>
          <population>Participants who received at least 1 dose of danicopan were included in the safety assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to Discontinuation of Study Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 (after dosing) through 24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Danicopan + Eculizumab</title>
          <description>Participants were administered 100, 150, or 200 mg danicopan TID in combination with eculizumab. Danicopan dose may have been increased within each participant, to a maximum of 200 mg TID based on safety and efficacy.&#xD;
The study was based on a flexible dosing design. Data from all participants were pooled for analysis.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Periorbital swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vaccination site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alexion Pharmaceuticals, Inc.</name_or_title>
      <organization>Alexion Pharmaceuticals, Inc.</organization>
      <phone>855-752-2356</phone>
      <email>clinicaltrials@alexion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

